Alternatives to Miebo If You Can't Fill Your Prescription

Miebo (perfluorohexyloctane) is a first-in-class dry eye treatment, but it isn't always easy to get. Whether you're dealing with insurance denials, pharmacy availability gaps, or cost concerns, knowing your alternatives gives you options. Below we compare the most widely prescribed alternatives to Miebo — all FDA-approved — and explain which type of patient each is best suited for.

Understanding Why Miebo Is Different

Before we dive into alternatives, it helps to understand what makes Miebo unique. Most prescription dry eye treatments — including Restasis, Cequa, Xiidra, and Vevye — work by reducing inflammation, which allows your tear glands to produce more natural tears. Miebo is different. It's a water-free, preservative-free semifluorinated alkane that physically forms a layer on the tear film to slow evaporation. It doesn't target inflammation — it targets the evaporation process itself.

This matters because dry eye has subtypes. If your dry eye is primarily evaporative (often due to meibomian gland dysfunction), Miebo is a particularly targeted choice. If it's primarily aqueous-deficient or inflammation-driven, an anti-inflammatory may work better — or be a useful complement to Miebo.

Alternative 1: Restasis (Cyclosporine 0.05%) — The Original Prescription Dry Eye Drop

Restasis (cyclosporine ophthalmic emulsion 0.05%, by AbbVie/Allergan) has been available since 2002 and is one of the most prescribed dry eye medications. It works by reducing inflammation in the lacrimal glands, allowing them to produce more natural tears over time.

Key facts about Restasis:

• Dosing: Twice daily (BID)
• Onset: Full effect may take 3–6 months
• Generic available: Yes (cyclosporine ophthalmic 0.05%), typically $85–$150 with discount card
• Side effects: Burning/stinging (common initially), eye redness, blurred vision
• Best for: Inflammation-driven aqueous-deficient dry eye

Alternative 2: Xiidra (Lifitegrast 5%) — Faster Onset, Different Mechanism

Xiidra (lifitegrast ophthalmic solution 5%, Novartis) works differently than cyclosporine. It blocks a protein called LFA-1 that drives the inflammatory cascade on the ocular surface. Some patients see improvement within 2–4 weeks — faster than cyclosporine-based medications.

Key facts about Xiidra:

• Dosing: Twice daily (BID)
• Onset: Improvement often seen at 2–4 weeks for symptoms
• Generic available: No
• Side effects: Dysgeusia (altered/metallic taste), eye redness, burning
• Best for: Patients who need faster relief; patients who failed cyclosporine

Alternative 3: Cequa (Cyclosporine 0.09%) — Higher-Strength Cyclosporine

Cequa (cyclosporine ophthalmic solution 0.09%, Sun Pharmaceuticals) delivers a higher concentration of cyclosporine than Restasis, using nanomicellar technology for improved corneal penetration. For patients who need more than Restasis offers, Cequa can be an effective step up.

Key facts about Cequa:

• Dosing: Twice daily (BID)
• Onset: As early as 4 weeks for some patients
• Cost workaround: Sun Pharmaceuticals offers $89/month direct pricing (equivalent to ~$29.67/month for a 3-month supply)
• Best for: Patients with moderate-to-severe DED who need enhanced cyclosporine delivery

Alternative 4: Vevye (Cyclosporine 0.1%) — Water-Free Cyclosporine

Vevye (cyclosporine ophthalmic solution 0.1%, Harrow) is a water-free, preservative-free cyclosporine eye drop that uses a semifluorinated alkane base — the same class of vehicles used in Miebo. The water-free formulation improves tolerability: many patients report less burning and stinging compared to Restasis. Vevye is approved for signs and symptoms of dry eye disease, including for patients with inflammation. Note: Vevye's vehicle is a shorter-chain SFA and does NOT have the same anti-evaporative effect as Miebo's perfluorohexyloctane.

Alternative 5: Tyrvaya (Varenicline Nasal Spray) — No Eye Drops Required

Tyrvaya (varenicline solution nasal spray 0.03 mg, Viatris) is a unique option for patients who can't tolerate eye drops at all. It works by activating the trigeminal nerve through the nasal cavity, triggering natural tear production from the lacrimal gland. It's approved for the signs and symptoms of dry eye disease. Side effects can include sneezing or nose irritation. It's dosed twice daily (BID).

How Do These Alternatives Compare to Miebo?

The key distinction is mechanism:

• Miebo targets evaporation directly — unique in its class
• Restasis, Cequa, Xiidra, Vevye target inflammation → more tear production
• Tyrvaya stimulates nerve pathways → increases natural tear output

Patients with primarily evaporative dry eye (the most common type) may not see the same benefit from anti-inflammatory drops as they would from Miebo. Your eye doctor can determine your dry eye subtype — often using meibography and tear film tests — and recommend the best match for you.

The Bottom Line

If you can't get Miebo right now, effective alternatives exist. The best next step is to call your prescriber, explain the access issue, and ask which alternative they recommend for your specific type of dry eye. You can also try medfinder to check pharmacies near you that may have Miebo in stock — it may save you from switching medications entirely.